[Serum argininosuccinate synthetase (ASS) in patients with chronic hepatitis C treated with interferon].
Serum ASS and serum GPT levels were determined in 16 patients with chronic hepatitis C treated with interferon. In all the patients, the serum ASS level decreased earlier than the serum GPT level, and this tendency was remarkable in patients who excellently responded to the treatment. Furthermore, the serum ASS level was fluctuated when the serum GPT levels being continuously flat in the course of the treatment, probably because of the shorter half life of ASS in the serum. In conclusion, the serum ASS level may catch the effect of interferon on inflammation in the liver more sensitively than the GPT.